CN107753628B - 一种治疗失眠的中药组合物及制备方法 - Google Patents
一种治疗失眠的中药组合物及制备方法 Download PDFInfo
- Publication number
- CN107753628B CN107753628B CN201610712902.7A CN201610712902A CN107753628B CN 107753628 B CN107753628 B CN 107753628B CN 201610712902 A CN201610712902 A CN 201610712902A CN 107753628 B CN107753628 B CN 107753628B
- Authority
- CN
- China
- Prior art keywords
- parts
- concentrated solution
- concentrating
- extracting
- filtrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 53
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 title claims abstract description 48
- 206010022437 insomnia Diseases 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 32
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 25
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 25
- 244000141009 Hypericum perforatum Species 0.000 claims abstract description 23
- 235000017309 Hypericum perforatum Nutrition 0.000 claims abstract description 23
- 238000002156 mixing Methods 0.000 claims abstract description 23
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 22
- 238000001035 drying Methods 0.000 claims abstract description 21
- 240000001341 Reynoutria japonica Species 0.000 claims abstract description 20
- 235000018167 Reynoutria japonica Nutrition 0.000 claims abstract description 20
- 235000011438 Albizia odoratissima Nutrition 0.000 claims abstract description 17
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 16
- 244000293323 Cosmos caudatus Species 0.000 claims abstract description 11
- 235000005956 Cosmos caudatus Nutrition 0.000 claims abstract description 11
- 239000002775 capsule Substances 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000008187 granular material Substances 0.000 claims abstract description 7
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims abstract description 3
- 239000006187 pill Substances 0.000 claims abstract description 3
- 240000000559 Albizia odoratissima Species 0.000 claims abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- 229940079593 drug Drugs 0.000 claims description 30
- 239000000706 filtrate Substances 0.000 claims description 27
- 238000001914 filtration Methods 0.000 claims description 27
- 238000000605 extraction Methods 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 17
- 210000000582 semen Anatomy 0.000 claims description 16
- 238000010298 pulverizing process Methods 0.000 claims description 13
- 239000000047 product Substances 0.000 claims description 12
- 238000003809 water extraction Methods 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 241000628997 Flos Species 0.000 claims description 8
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- 235000021419 vinegar Nutrition 0.000 claims description 8
- 239000000052 vinegar Substances 0.000 claims description 8
- 241000218202 Coptis Species 0.000 claims description 3
- 235000002991 Coptis groenlandica Nutrition 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 39
- 239000008280 blood Substances 0.000 abstract description 23
- 210000004369 blood Anatomy 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 19
- 206010038743 Restlessness Diseases 0.000 abstract description 15
- 208000001431 Psychomotor Agitation Diseases 0.000 abstract description 14
- 230000007812 deficiency Effects 0.000 abstract description 13
- 230000001914 calming effect Effects 0.000 abstract description 9
- 230000006870 function Effects 0.000 abstract description 7
- 238000009776 industrial production Methods 0.000 abstract description 3
- 208000011580 syndromic disease Diseases 0.000 abstract description 3
- 229940126673 western medicines Drugs 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 46
- 241000699670 Mus sp. Species 0.000 description 31
- 230000007958 sleep Effects 0.000 description 24
- 244000132619 red sage Species 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 241000220433 Albizia Species 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 11
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 10
- 244000126002 Ziziphus vulgaris Species 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 9
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 9
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 8
- 229960001412 pentobarbital Drugs 0.000 description 8
- 238000012423 maintenance Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 206010033557 Palpitations Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000004620 sleep latency Effects 0.000 description 5
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 5
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 229960003529 diazepam Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 229960002275 pentobarbital sodium Drugs 0.000 description 4
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 4
- 240000007164 Salvia officinalis Species 0.000 description 3
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000028527 righting reflex Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241000406668 Loxodonta cyclotis Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 235000017276 Salvia Nutrition 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 2
- 240000008866 Ziziphus nummularia Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- VGGSULWDCMWZPO-ODEMIOGVSA-N spinosin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=2C(=O)C=C(OC=2C=C1OC)C=1C=CC(O)=CC=1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VGGSULWDCMWZPO-ODEMIOGVSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 240000007185 Albizia julibrissin Species 0.000 description 1
- 235000011468 Albizia julibrissin Nutrition 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000489492 Arisaema Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 229930182476 C-glycoside Natural products 0.000 description 1
- -1 C-glycoside flavone Chemical class 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 241000546193 Clusiaceae Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical group OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- VGGSULWDCMWZPO-UHFFFAOYSA-N flavoayamenin Natural products COC1=CC=2OC(C=3C=CC(O)=CC=3)=CC(=O)C=2C(O)=C1C1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O VGGSULWDCMWZPO-UHFFFAOYSA-N 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008876 liujunzi Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
- 229910052957 realgar Inorganic materials 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000009396 suanzaoren Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开一种治疗失眠的中药组合物及制备方法。该组合物由下列重量份的原料制得:炒酸枣仁10~100份,夜交藤10~50份,柏子仁5~50份,醋五味子5~30份,黄连5~30份,合欢花5~30份,丹参5~50份,贯叶金丝桃5~25份,珍珠粉0.2~2份。将上述药物进行提取、浓缩得到浓缩液干燥后,再加入珍珠粉混匀,可用于制备片剂、口服液、颗粒剂、滴丸或胶囊剂。本发明所提供的组合物,具有养血安魂,清热除烦功能,主治肝血不足,虚热内扰证之不寐,症见入睡困难,多梦易醒,或早醒,难以再睡,心烦不宁,舌红,脉弦细,适用于失眠障碍见上述证候者,相对于某些西药而言,副作用较小,且适合工业化生产。
Description
技术领域
本发明涉及一种治疗失眠的药物领域,尤其涉及一种治疗失眠的中药组合物及制备方法。
背景技术
根据中华医学会神经病学分会睡眠障碍学组2012年发布的《中国成人失眠诊断与治疗指南》,失眠是指患者对睡眠时间和(或)质量不满足并影响日间社会功能的一种主观体验。其主要表现为入睡困难、维持睡眠困难、过早觉醒和睡后无恢复感,可引起躯体功能障碍或明显不适。流行病学调查表明,失眠率高达10%~20%。据估计,到2020年全球失眠者将超过7亿。一般来说,女性失眠率略高于男性,老年人失眠率高于其他年龄组。另外,50岁以上失眠者占总失眠人数的40%。日益加快的生活节奏及激烈的竞争,是失眠病例增加的一个重要原因。睡眠不好还会造成人的认知功能下降,免疫功能减退,进而导致生活和工作质量降低。目前失眠的主要治疗手段还是药物治疗,而主要药物为安定等西药,虽然治疗失眠效果明显,但其副作用大。
中医认为魂是五神之一,是潜于神之中的随神往来生灭的一种潜意识,主要包括谋略、梦幻和志怒、惊恐之类的情感活动。如《灵枢·本神》曰:“随神往来者,谓之魂。”明·张景岳《类经·藏象论》注:“魂之为言,如梦寐恍惚,变幻游行之境皆是也。”《素问·宣明五气篇》云:“五藏所藏,……肝藏魂。”《灵枢·本神》云:“肝藏血,血舍魂。”《素问·六节藏象论》曰:“肝者,罢极之本,魂之居也。”生理上,魂依肝血而寄生,血载魂而出入,故有睡眠和觉醒。病理上,魂因肝气而不藏,受肝邪而难藏,故有不寐和梦幻。如《灵枢·本神》云:“肝,悲哀动中则伤魂,魂伤则狂妄不精。”宋·许叔微《普济本事方·卷一》曰:“平人肝不受邪,故卧则魂归于肝,神静而得寐。今肝有邪,魂不得归,是以卧则魂扬若离体也。”肝郁化火,阴血暗耗,肝血不足,不能舍魂,或血虚肝旺,虚热内扰,魂不守舍,故虚烦不得眠、入睡困难,多梦易醒,或早醒,难以再睡,心烦不宁。舌红、脉细弦或数,为阴虚内热之象。基于上述认识,古人和今人创造了大量的方剂,很多方剂也具有确实的疗效,但是,很多方剂都是个性化的治疗方案,鲜有能够适合工业化生产的中药方剂。
发明内容
鉴于现有技术的不足,本发明旨在提供一种治疗失眠的中药组合物及其制备方法。
本发明采用的技术方案为:一种治疗失眠的中药组合物,其有效成分原料药质量份数为:炒酸枣仁10~100份,夜交藤10~50份,柏子仁5~50份,醋五味子5~30份,黄连5~30份,合欢花5~30份,丹参5~50份,贯叶金丝桃5~25份,珍珠粉0.2~2份。
进一步地,一种治疗失眠的中药组合物,其有效成分原料药质量份数为:炒酸枣仁40~80份,夜交藤15~30份,柏子仁10~30份,醋五味子10~20份,黄连10~20份,合欢花5~20份,丹参5~30份,贯叶金丝桃5~20份,珍珠粉0.3~1份。
进一步地,一种治疗失眠的中药组合物,其有效成分原料药质量份数为:炒酸枣仁50份,夜交藤10份,柏子仁10份,醋五味子10份,黄连9份,合欢花6份,丹参6份,贯叶金丝桃6份,珍珠粉0.6份。
本发明还提供该种治疗失眠的中药组合物的制备方法,所述制备方法具体步骤如下:
取炒酸枣仁10~100份,夜交藤10~50份,柏子仁5~50份,醋五味子5~30份,黄连5~30份,合欢花5~30份,丹参5~50份,贯叶金丝桃5~25份;
将上述药物进行提取、浓缩得到浓缩液后,再加入珍珠粉0.2~2份混匀,可用于制备片剂、口服液、颗粒剂、滴丸或胶囊剂。
优选地,将丹参、醋五味子混合后,于多功能提取灌中加入6~15倍量的50~80%乙醇进行提取,提取时间为0.5~3h,提取2~3次,合并提取液,纱布过滤,滤液在单效浓缩器中浓缩,浓缩条件为:压力-0.08MPa,温度60-70℃,浓缩至相对密度为1.10~1.30的浓缩液1;
上述药渣与炒酸枣仁、柏子仁、合欢花、贯叶金丝桃、夜交藤,加入5~15倍量的水进行提取,提取时间为0.5~3h,提取2~3次,合并提取液,纱布过滤,滤液在单效浓缩器中浓缩,浓缩条件为:压力-0.08MPa,温度60-70℃,浓缩至相对密度为1.10~1.30的浓缩液2;
将黄连加入5~15倍量的水进行提取,提取时间为0.5~3h,提取2~3次,合并提取液,纱布过滤,滤液在单效浓缩器中浓缩,浓缩条件为:压力-0.08MPa,温度60-70℃,浓缩至相对密度为1.10~1.30的浓缩液3。将上述浓缩液1、2、3和珍珠粉加入适当辅料,并制成相应的剂型。
优选地,将炒酸枣仁,夜交藤,柏子仁和合欢花进行适当粉碎,于多功能提取灌中加入8~10倍量的70%乙醇进行提取,提取时间为2h,提取2次,合并提取液,纱布过滤,滤液在单效浓缩器中浓缩,浓缩条件为:压力-0.08MPa,温度60℃,浓缩至相对密度为1.28~1.30的浓缩液1;
上述药渣与醋五味子,黄连,丹参和贯叶金丝桃混合均匀,加入8~10倍量的水进行提取,提取时间为2h,提取2次,合并提取液,纱布过滤,滤液在单效浓缩器中浓缩,浓缩条件为:压力-0.08MPa,温度70℃,浓缩至相对密度为1.28~1.30的浓缩液2;
将上述浓缩液1、2和珍珠粉加入适当辅料,并制成相应的剂型。
本发明的部分药材解析如下:
酸枣仁(拉丁名称:Semen Ziziphi Spinosae)为鼠李科植物酸枣干燥成熟种子。味甘、酸,性平。归肝、胆、心经。具有养血补肝,宁心安神。用于虚烦不眠,惊悸多梦,体虚多汗,津伤口渴。《本草图经》:“酸枣仁,《本经》主烦心不得眠,今医家两用之,睡多生使,不得睡炒熟,生熟便尔顿异。”《医宗必读》:“愚按《内经》及前哲诸论,详考之而知不寐之故大约有五:一曰气虚六君子汤加酸枣仁、黄芪;一曰阴虚,血少心烦,酸枣仁一两、生地黄五钱、米二合,煮粥食之;一曰痰滞,温胆汤加南星、酸枣仁、雄黄末…。”从酸枣仁中提取的酸枣仁皂苷(jujubosides)具有显著的催眠作用,酸枣仁棘苷(spinosin)(一种C-糖苷黄酮)通过血清素1A(5-羟色胺(1A))受体显著增强戊巴比妥(35mg/kg,ip)诱导大鼠的睡眠,其对在戊巴比妥处理大鼠的快速眼球运动(REM)睡眠的效果可能与突触后5-羟色胺(1A)受体有关。
紫丹参(拉丁学名:Salvia miltiorrhiza Bunge)为双子叶植物唇形科鼠尾草属多年生直立草本植物。味苦,性微寒。具有祛瘀止痛,活血通经,清心除烦功能。用于月经不调,经闭痛经,症瘕积聚,胸腹刺痛,热痹疼痛,疮疡肿痛,心烦不眠;肝脾肿大,心绞痛。《本草纲目》:丹参,按《妇人明理论》云,四物汤治妇人病,不问产前产后,经水多少,皆可通用,惟一味丹参散,主治与之相同。盖丹参能破宿血,补新血,安生胎,落死胎,止崩中滞下,调经脉,其功大类当归、地黄、芎穷、芍药故也。《滇南本草》:补心定志,安神宁心。治健忘怔忡,惊悸不寐。
醋北五味子(拉丁学名:Schisandra chinensis)为木兰科植物五味子的干燥成熟果实。味酸、甘,性温,归肺、肝、肾经。具有收敛固涩、益气生津、补肾安魂功能。用于久嗽虚喘,自汗,盗汗,津伤口渴,短气脉虚,内热消渴;梦遗滑精,遗尿尿频,久泻不止;心悸失眠。五味子中含五味子素(Schisandrin)有广泛的中枢抑制作用,并且有催眠作用的特点,其作用不是直接抑制中枢神经系统而是抑制了肝脏对戊巴比妥钠的代谢。
贯叶金丝桃(拉丁学名:Hypericum perforatum),又名贯叶连翘,为藤黄科植物贯叶金丝桃的干燥地上部分。味辛,性寒,归肝经。其金丝桃素(hypericin)提取物参与基因控制下丘脑-垂体-肾上腺轴功能的调节,具有治疗抑郁、神经损伤和失眠的作用。
复方枣仁颗粒是根据全国第五批名老中医药专家田金洲教授的经验方研制而成。该方最早由田金洲教授整理已故董建华院士临床经验时发现,命名为丹参枣仁汤,由丹参、生龙骨、生牡蛎、夜交藤、合欢皮,炒酸枣仁、柏子仁7味药组成。
复方枣仁颗粒是在丹参枣仁汤基础上去生龙骨、生牡蛎,合欢皮改合欢花,加五味子、黄连、珍珠粉、贯叶金丝桃组成。因生龙骨、生牡蛎为重镇安神药,属对症治标之品,且龙骨属矿物类药,久服易伤脾胃,故在改良的复方枣仁颗粒处方中弃之不用。相对于合欢皮,合欢花更适合治疗虚烦不眠,契合本病的虚热内扰证型;同时使用花朵不用树皮,也有利于自然资源的保护。五味子善治阴血亏虚之虚烦心悸,失眠多梦;珍珠粉甘、咸、寒,归心、肝经,能镇静安神,善治心神不宁之失眠。贯叶金丝桃可解肝气郁结,情志不畅。黄连善清心火肝火,协助其他药物增强清热除烦的作用。
本方新的配伍增强了养血安魂,清热除烦的功效,更适合肝血不足,虚热内扰证之不寐的治疗。本方以炒酸枣仁为君药,补肝养血,宁心安魂,对入睡困难和维持睡眠有明确疗效。丹参、柏子仁、夜交藤、五味子具滋养营血,补肝敛魂,可增加酸枣仁之力,故为臣药。黄连、珍珠粉清肝镇惊,除烦宁魂,有助于减轻入睡困难症状,故为佐药;合欢花、贯叶金丝桃疏肝解郁,宁神安魂,有助于改善睡眠质量和减轻早醒症状。全方具有养血安魂,清热除烦功能,体现了从肝论治失眠的临床经验,即养肝、清肝、疏肝。主治肝血不足,虚热内扰证之不寐,症见入睡困难,多梦易醒,或早醒,难以再睡,心烦不安或担忧睡眠,舌红,脉弦细。适用于失眠障碍见上述证候者。
本发明所提供治疗失眠的中药组合物,具有养血安魂,清热除烦功能,主治肝血不足,虚热内扰证之不寐,症见入睡困难,多梦易醒,或早醒,难以再睡,心烦不宁,舌红,脉弦细,适用于失眠障碍见上述证候者,相对于安定等西药而言,副作用较小,且适合工业化生产。
具体实施方式
以下结合实施例,对本发明进行更加详细的说明,以便能够更好地理解本发明的方案及其各个方面的优点。然而,以下描述的实施例仅是说明的目的,而不是对本发明的限制。
实施例1
取炒酸枣仁50份,夜交藤10份,柏子仁10份,醋五味子10份,黄连9份,合欢花6份,丹参6份,贯叶金丝桃6份,珍珠粉0.6份。
醇提:将上述炒酸枣仁,夜交藤,柏子仁和合欢花分别进行适当粉碎,混合后,置于多功能提取灌中,并加入8~10倍量的70%乙醇进行提取,提取时间为2h,提取2次,合并提取液,纱布过滤,滤液在单效浓缩器中浓缩,浓缩条件为:压力-0.08MPa,温度60℃,浓缩至相对密度为1.28~1.30的浓缩液A。
水提:将上述药渣与醋五味子,黄连,丹参和贯叶金丝桃混合均匀,加入8~10倍量的水进行提取,提取时间为2h,提取2次,合并提取液,纱布过滤,滤液在单效浓缩器中浓缩,浓缩条件为:压力-0.08MPa,温度70℃,浓缩至相对密度为1.28~1.30的浓缩液B。
干燥:将浓缩液A、浓缩液B置于带式干燥机中干燥,干燥时间为2h,干燥温度为85℃,得干燥物,然后对干燥物进行粉碎,再加入珍珠粉和药用辅料制成所需的中药复方制剂。
实施例2
取炒酸枣仁100份,夜交藤10份,柏子仁5份,醋五味子5份,黄连15份,合欢花10份,丹参5份,贯叶金丝桃10份,珍珠粉0.2份。
水提:将原料药各组分进行适当粉碎(除珍珠粉外),混合后,于多功能提取灌中加入8~10倍量的水进行提取,提取时间为2h,提取2次,合并提取液,纱布过滤,滤液在单效浓缩器中浓缩,浓缩条件为:压力-0.08MPa,温度70℃,浓缩至相对密度为1.13~1.15的浓缩液A。
醇沉:浓缩液A缓慢加入乙醇,边加边搅拌,使最终醇浓度达到70%,放置过夜,过滤,取上清液,于减压浓缩器中浓缩,浓缩条件为:压力-0.08MPa,温度65℃,浓缩至相对密度为1.28~1.30的浓缩液B。
干燥:将浓缩液B置于带式干燥机中干燥,干燥时间为2h,干燥温度为85℃,得干燥物,然后对干燥物进行粉碎,再加入珍珠粉和药用辅料制成所需的中药复方制剂。
实施例3
取炒酸枣仁10份,夜交藤50份,柏子仁50份,醋五味子20份,黄连5份,合欢花30份,丹参50份,贯叶金丝桃5份,珍珠粉1份。
水提:将原料药各组分进行适当粉碎(除珍珠粉外),混合后,于多功能提取灌中加入8~10倍量的水进行提取,提取时间为2h,提取2次,合并提取液,纱布过滤,滤液在单效浓缩器中浓缩,浓缩条件为:压力-0.08MPa,温度60℃,浓缩至相对密度为1.28~1.30的浓缩液A。
干燥:将浓缩液A置于带式干燥机中干燥,干燥时间为2h,干燥温度为85℃,得干燥物,然后对干燥物进行粉碎,再加入珍珠粉和药用辅料制成所需的中药复方制剂。
实施例4
取炒酸枣仁60份,夜交藤10份,柏子仁10份,醋五味子30份,黄连30份,合欢花5份,丹参6份,贯叶金丝桃25份,珍珠粉2份。
醇提:取酸枣仁,于多功能提取灌中加入8~10倍量的70%乙醇进行提取,提取时间为2h,提取2次,提取液以纱布过滤,滤液于减压浓缩器中浓缩,浓缩条件为:压力-0.08MPa,温度60℃,浓缩至相对密度为1.13-1.15的浓缩液,上非极性或弱极性大孔吸附树脂(例如:D101和AB-8、DS-401),上柱后静态吸附2小时,用3倍柱体积的水和30%乙醇除杂,后用60%~80%乙醇洗脱,收集洗脱液,于旋转蒸发仪上浓缩至相对密度1.28~1.30的浓缩液A。将夜交藤,柏子仁和合欢花进行适当粉碎,混合后,于多功能提取灌中加入8~10倍量的70%乙醇进行提取,提取时间为2h,提取2次,合并提取液,纱布过滤,滤液在单效浓缩器中浓缩,浓缩条件为:压力-0.08MPa,温度60℃,浓缩至相对密度为1.28~1.30的浓缩液B。
水提:上述干燥物B药渣与醋五味子,黄连,丹参和贯叶金丝桃混合均匀,加入8~10倍量的水进行提取,提取时间为2h,提取2次,合并提取液,纱布过滤,滤液在单效浓缩器中浓缩,浓缩条件为:压力-0.08MPa,温度70℃,浓缩至相对密度为1.28~1.30的浓缩液C。
干燥:将浓缩液A、浓缩液B和浓缩液C置于带式干燥机中干燥,干燥时间为2h,干燥温度为85℃,得干燥物,然后对干燥物进行粉碎,再加入珍珠粉和药用辅料制成所需的中药复方制剂。
实施例5
取炒酸枣仁40份,夜交藤20份,柏子仁10份,醋五味子15份,黄连10份,合欢花10份,丹参15份,贯叶金丝桃6份,珍珠粉0.6份。
醇提:将丹参和醋五味子分别粉碎,混合后,用8~10倍量的70%乙醇进行提取,提取时间为2h,提取2次,合并提取液,纱布过滤,滤液在单效浓缩器中浓缩,浓缩条件为:压力-0.08MPa,温度60℃,浓缩至相对密度为1.28~1.30的浓缩液A。
水提:将上述药渣与炒酸枣仁、柏子仁、合欢花、贯叶金丝桃和夜交藤混合均匀,加入8~10倍量的水进行提取,提取时间为2h,提取2次,合并提取液,纱布过滤,滤液在单效浓缩器中浓缩,浓缩条件为:压力-0.08MPa,温度70℃,浓缩至相对密度为1.28~1.30的浓缩液B。;
水提:将黄连药材粉碎,加入8~10倍量的水进行提取,提取时间为2h,提取2次,合并提取液,纱布过滤,滤液在单效浓缩器中浓缩,浓缩条件为:压力-0.08MPa,温度70℃,浓缩至相对密度为1.28~1.30的浓缩液C。;
其中干燥的步骤包括:将浓缩液A、浓缩液B、浓缩液C,分别置于带式干燥机中干燥,干燥时间为2h,干燥温度为85℃,得干燥物,然后对干燥物进行粉碎、混合,再加入珍珠粉和药用辅料制成所需的中药复方制剂。
药物与戊巴比妥钠协同睡眠作用
1.实验目的
小鼠给予阈上剂量戊巴比妥钠,考察本发明技术方案中颗粒剂对延长戊巴比妥钠睡眠作用。
2.实验材料
2.1实验动物
KM小鼠130只,体重18-22g,雌雄各半,由北京维通利华实验技术有限公司提供,生产许可证:SCXK(京)2012-0001,质量合格证:11400700155588。
2.2药物及试剂
三批样品,由江苏康缘药业股份有限公司提供FFZR-1;FFZR-2;
FFZR-3。
戊巴比妥钠,由SIGMA公司提供,批号:20150516
地西泮,江苏济川制药有限公司,批号:140401,分装时间:2015.12.16枣仁安神胶囊,贵州同济堂制药有限公司,批号:150402。
2.3实验仪器
电子天平,BSM220型,上海卓精电子科技有限公司;
三峰牌计重秤,ACS-DⅡ型,上海乾峰电子仪器有限公司。
3.实验条件
小鼠接收后放入实验室环境中分笼饲养,保持环境温度20~25℃,湿度40~70%。饲以实验鼠用配合饲料,自由进食饮水。
4.统计方法
5.药物配制
配制信息详见表1
表1受试物配制信息
6.实验方法
6.1分组及给药
小鼠正常适应性饲养约3天后开始实验,选择体重在18-22g小鼠72只,随机分为6组,即模型组、枣仁安神胶囊组、地西泮组、FFZR-1、FFZR-2、FFZR-3,每组12只,雌雄各半。各组小鼠分别给予相应药物,枣仁安神胶囊组给予枣仁安神胶囊0.6g/kg,地西泮组给予地西泮1.3mg/kg,FFZR-1组给予3.18g生药/kg,FFZR-2组给予3.21g生药/kg,FFZR-3组给予3.12g生药/kg,模型组给予等体积蒸馏水,给药体积为20ml/kg。
6.2戊巴比妥钠所致小鼠睡眠阈上剂量的确定
阈上剂量的确定:体重18-22g小鼠24只,分为3个剂量组,分别腹腔注射戊巴比妥钠50mg/kg、45mg/kg、40mg/kg,以所有给药小鼠翻正反射均消失的最小剂量作为阈上剂量。
小鼠的翻正反射:用手轻轻地将小鼠侧卧或仰卧,小鼠能立即翻正体位、恢复正常姿势,说明翻正反射存在;将小鼠置于背卧位时,如超过30-60秒不能翻正者,即认为翻正反射消失,进入睡眠。
6.3检测指标
给药30min后,各小鼠分别腹腔注射给予阈上剂量的戊巴比妥钠,记录小鼠进入睡眠的时间、睡眠维持时间,观察结束后脱颈椎处死实验小鼠及体重筛选不合格小鼠。
7.实验结果
结果见表2,小鼠腹腔注射给予50mg/ml戊巴比妥钠后,与模型组比较,地西泮组小鼠睡眠潜伏期明显缩短(P<0.05),睡眠维持时间明显延长(P<0.01);枣仁胶囊组而睡眠维持时间有所延长,但与模型无显著性差异(P>0.05);FFZR-1睡眠潜伏期有所减少,睡眠维持时间增加,但与模型无显著差异(P>0.05),FFZR-2组与FFZR-3组小鼠睡眠维持时间均明显增加,与模型组比较有显著差异(P<0.01),且FFZR-3组睡眠潜伏期明显减少,与模型组有显著差异(P<0.05)。
与模型组比较,**P<0.01,*P<0.05
8.结论
按本发明技术方案下处方,所制备的样品,在临床剂量下均能有效缩短小鼠睡眠潜伏期,而对照组枣仁胶囊需在两倍临床剂量下才能接近本品药效作用;三个实验组在睡眠维持方面均优于枣仁胶囊组其中2、3组与化学药地西泮组相当。提取本中药复方在动物体内药效试验中其缩短动物睡眠潜伏期,延长动物睡眠维持时间作用明显优于同类中药品种。
药物单次给药毒性考察
1.实验目的
采用小鼠灌胃给药方法,观察给药后动物的反应及毒性
2.实验材料
2.1实验动物
昆明小鼠,40只,体重18-22g,雌雄各半,由北京维通利华实验技术有限公司提供,生产许可证:SCXK(京)2012-0001,质量合格证:11400700155588。
2.2药品及试剂
三批样品,由江苏康缘药业股份有限公司提供FFZR-1;FFZR-2;FFZR-3。
2.3仪器使用
电子天平,BSM220型,上海卓精电子科技有限公司;
三峰牌计重秤,ACS-DⅡ型,上海乾峰电子仪器有限公司;
3.实验条件
给药前后,实验动物雌雄分笼,用实验鼠颗粒饲料(由南京市青龙山动物繁殖场提供)喂养,自由饮水,温度20~25℃,湿度40~70%。
4.统计方法
本实验量反应资料采用t-text检验法,统计软件用微软Excel软件。
5.样品配制信息
6.分组及给药
取小鼠40只,体重18~22g,雌雄各半,分为空白组和工艺1组、工艺2组、工艺3组,每组10只。实验前禁食不禁水12小时,FFZR-1组给予100.11g生药/kg,FFZR-2组给予83.38g生药/kg,FFZR-3组给予84.11g生药/kg,给药体积为30ml/kg,一次给药,空白组给予等量蒸馏水。
给药当日详细观察给药后4h内小鼠的反应情况;连续饲养7日,每日上、下午各观察一次动物的反应情况(包括各小鼠外观体征和行为活动、粪便性状等)及死亡情况。第14日小鼠称重,比较空白组和给药组小鼠体重增长率;脱颈椎处死后,尸检小鼠心、肝、脾、肺、肾等重要脏器,观察各组小鼠有无肉眼可见的病理改变,如有病变,则进行病理切片检查。
7.实验结果
给药当天各组小鼠活动均有所减少,摄食量减少,第二天给药组小鼠粪便颜色较深,其他无异常,小鼠体重增长正常,尸检小鼠心、肝、脾、肺、肾等肉眼均未见异常。小鼠体重增长率及摄食量见表3、表4。
表3小鼠体重变化
表4小鼠摄食量变化(g/只/天)
结论:本处方组成制备所得样品,在考察剂量下未见明显毒性,提示该药物组成安全性良好。
需要说明的是,以上仅是本发明的优选实施方式,上述优选实施方式不应视为对本发明的限制,本发明的保护范围应当以权利要求所限定的范围为准。对于本技术领域的普通技术人员来说,在不脱离本发明的精神和范围内,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。此外,除上下文另有所指外,以单数形式出现的词包括复数形式,反之亦然。另外,除非特别说明,那么任何实施例的全部或一部分可结合任何其它实施例的全部或一部分来使用。
Claims (9)
1.一种治疗失眠的中药组合物,由下列重量份的原料制得:
炒酸枣仁40~80份,夜交藤15~30份,柏子仁10~30份,醋五味子10~20份,黄连10~20份,合欢花5~20份,丹参5~30份,贯叶金丝桃5~20份,珍珠粉0.3~1份。
2.一种治疗失眠的中药组合物,由下列重量份的原料制得:
炒酸枣仁50份,夜交藤10份,柏子仁10份,醋五味子10份,黄连9份,合欢花6份,丹参6份,贯叶金丝桃6份,珍珠粉0.6份。
3.一种治疗失眠的中药组合物的制备方法,其特征在于,
取炒酸枣仁40~80份,夜交藤15~30份,柏子仁10~30份,醋五味子10~20份,黄连10~20份,合欢花5~20份,丹参5~30份,贯叶金丝桃5~20份;
将上述药物进行提取、浓缩得到浓缩液后,再加入珍珠粉0.3~1份混匀,用于制备片剂、口服液、颗粒剂、滴丸或胶囊剂。
4.根据权利要求3所述的制备方法,其特征在于,其中提取的步骤包括:
醇提:将丹参和醋五味子分别粉碎,混合后,用乙醇进行提取,过滤,滤液浓缩后得到浓缩液A;
水提:将醇提药渣与炒酸枣仁、柏子仁、合欢花、贯叶金丝桃和夜交藤混合均匀,用水进行提取,过滤,滤液浓缩后得到浓缩液B;将黄连用水进行提取,过滤,滤液浓缩后得到浓缩液C;
其中干燥的步骤包括:对浓缩液A、浓缩液B和浓缩液C进行干燥,然后对干燥后所得物进行粉碎,再加入珍珠粉和药学上可接受的辅料,制成所需的中药复方制剂。
5.根据权利要求3所述的制备方法,其特征在于,其中提取的步骤包括:
醇提:将炒酸枣仁,夜交藤,柏子仁和合欢花分别粉碎,混合后,用乙醇进行提取,过滤,滤液浓缩后得到浓缩液A;
水提:将醇提药渣与醋五味子、贯叶金丝桃、黄连和丹参混合均匀,用水进行提取,过滤,滤液浓缩后得到浓缩液B;
其中干燥的步骤包括:对浓缩液A、浓缩液B进行干燥,然后对干燥后所得物进行粉碎,再加入珍珠粉和药学上可接受的辅料,制成所需的中药复方制剂。
6.根据权利要求3所述的制备方法,其特征在于,其中提取的步骤包括:
水提:将炒酸枣仁,夜交藤,柏子仁、合欢花、醋五味子、贯叶金丝桃、黄连和丹参分别粉碎,混合后,用水进行提取,过滤,滤液浓缩后得到浓缩液A;
醇沉:往浓缩液中加入乙醇,搅拌,过滤,滤液浓缩后得到浓缩液B;
其中干燥的步骤包括:对浓缩液B进行干燥,然后对干燥后所得物进行粉碎,再加入珍珠粉和药学上可接受的辅料,制成所需的中药复方制剂。
7.根据权利要求3所述的制备方法,其特征在于,其中提取的步骤包括:
水提:将炒酸枣仁,夜交藤,柏子仁、合欢花、醋五味子、贯叶金丝桃、黄连和丹参分别粉碎,混合后,用水进行提取,过滤,滤液浓缩后得到浓缩液A;
其中干燥的步骤包括:对浓缩液A进行干燥,然后对干燥后所得物进行粉碎,再加入珍珠粉和药学上可接受的辅料制成所需的中药复方制剂。
8.根据权利要求3所述的制备方法,其特征在于,其中提取的步骤包括:
醇提:将炒酸枣仁用醇进行提取,过滤,滤液浓缩后,分离纯化进一步浓缩得到浓缩液A;将夜交藤,柏子仁、合欢花粉碎,混合后,用醇进行提取,过滤,滤液浓缩后得到浓缩液B;
水提:将醇提药渣与醋五味子、贯叶金丝桃、黄连和丹参混合均匀,用水进行提取,过滤,滤液浓缩后得到浓缩液C;
其中干燥的步骤包括:对浓缩液A、浓缩液B和浓缩液C进行干燥,然后对干燥后所得物进行粉碎,再加入珍珠粉和药学上可接受的辅料制成所需的中药复方制剂。
9.根据权利要求4-8任一所述的制备方法,其特征在于,所述药学上可接受的辅料为乳糖;所述中药复方制剂为经过制粒、整粒、分装后得到的颗粒剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610712902.7A CN107753628B (zh) | 2016-08-23 | 2016-08-23 | 一种治疗失眠的中药组合物及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610712902.7A CN107753628B (zh) | 2016-08-23 | 2016-08-23 | 一种治疗失眠的中药组合物及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107753628A CN107753628A (zh) | 2018-03-06 |
CN107753628B true CN107753628B (zh) | 2021-03-05 |
Family
ID=61264857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610712902.7A Active CN107753628B (zh) | 2016-08-23 | 2016-08-23 | 一种治疗失眠的中药组合物及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107753628B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109248201B (zh) * | 2018-10-16 | 2021-07-27 | 江苏康缘药业股份有限公司 | 一种中药组合物及其在制备治疗心律失常药物中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1973889A (zh) * | 2006-11-07 | 2007-06-06 | 任广来 | 一种治疗失眠症的中药药物 |
CN102370781A (zh) * | 2011-11-24 | 2012-03-14 | 王成祥 | 一种治疗失眠症的中药制剂 |
CN102406854A (zh) * | 2011-11-22 | 2012-04-11 | 荣成市交通诊所 | 一种治疗不寐的中药组合物 |
-
2016
- 2016-08-23 CN CN201610712902.7A patent/CN107753628B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1973889A (zh) * | 2006-11-07 | 2007-06-06 | 任广来 | 一种治疗失眠症的中药药物 |
CN102406854A (zh) * | 2011-11-22 | 2012-04-11 | 荣成市交通诊所 | 一种治疗不寐的中药组合物 |
CN102370781A (zh) * | 2011-11-24 | 2012-03-14 | 王成祥 | 一种治疗失眠症的中药制剂 |
Non-Patent Citations (1)
Title |
---|
柏枣宁心颗粒治疗失眠症156例;周健等;《新中医》;20080229;第40卷(第02期);第76-77页 * |
Also Published As
Publication number | Publication date |
---|---|
CN107753628A (zh) | 2018-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101513493A (zh) | 一种治疗失眠的药物组合物及其制备方法 | |
CN107950929A (zh) | 一种具有改善睡眠功能的组合物及其制备方法和用途 | |
CN106728261B (zh) | 一种治疗失眠的药物组合物 | |
CN102475830B (zh) | 一种治疗冠心病心绞痛的药物组合物与其制备方法及制剂 | |
CN109528800A (zh) | 一种淫羊藿总黄酮提取物及制备方法和改善睡眠活性应用 | |
CN111840394B (zh) | 一种用于失眠的药物组合物及其制备方法 | |
CN105853527A (zh) | 一种含元宝枫的具有改善睡眠功能的中药组合物及其应用 | |
CN107753628B (zh) | 一种治疗失眠的中药组合物及制备方法 | |
CN102258742A (zh) | 一种治疗抑郁症的中药组合物及其制备方法 | |
CN105456818A (zh) | 一种含有艾叶的治疗失眠的中药组合物及其制备方法 | |
CN110101789A (zh) | 治疗失眠的中药制剂 | |
CN104938727A (zh) | 一种抗失眠代用茶的制备方法 | |
CN106309809B (zh) | 一种清心神安颗粒及其制备方法 | |
CN104623314A (zh) | 用于治疗口干口苦的药物组合物及其制备方法 | |
CN110960632B (zh) | 一种改善睡眠产品的配方及其制备方法 | |
CN113713048A (zh) | 固体形式的天麻醒脑中药组合物及其制法和用途 | |
CN105106547A (zh) | 一种用于治疗神经衰弱的药物制剂 | |
CN100428942C (zh) | 一种养心安神药物及其制备方法 | |
CN104920742A (zh) | 一种抗失眠代用茶 | |
CN104940696A (zh) | 一种治疗肝经湿热型小儿遗尿的药物及其制备方法 | |
CN105535587A (zh) | 一种治疗心肾不交型心悸失眠的中药制剂及其制备方法 | |
CN104623352B (zh) | 一种改善睡眠的药物组合物 | |
CN110201056A (zh) | 一种中药组合物及其制剂、制备方法和应用 | |
CN109758506B (zh) | 具有改善睡眠功能的中药保健食品及其制备方法 | |
CN103845447B (zh) | 一种具有益气健脾养肝、养血养心安神功能的纯中药养生制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |